Media OutReach
Shenzhen and Hong Kong Join Hands to Promote the Development of the Hetao Shenzhen-Hong Kong Science & Technology Innovation Co-operation Zone
“Driving the Globalization of Clinical Trials in the Guangdong-Hong Kong-Macao Greater Bay Area, Implementing the First Key Cross-Border Multi-Center Clinical Trial Project”
HONG KONG SAR – Media OutReach Newswire – 30 July 2025 – The Greater Bay Area International Clinical Trial Institute of Hong Kong (“GBAICTI“), the Greater Bay Area International Clinical Trials Center of Shenzhen (“BAY TRIAL“), Immuno Cure BioTech (“Immuno Cure“) in Hong Kong are pleased to jointly announce today the signing of a tripartite Memorandum of Understanding (“MOU“) in Shenzhen on July 29, 2025. This collaboration aims to advance the globalization of clinical trials in the Guangdong-Hong Kong-Macau Greater Bay Area (“GBA“), further deepens clinical research cooperation between Hong Kong and Shenzhen, and implements the first ever cross-border multi-centre Phase II clinical trial project for ICVAX, a therapeutic DNA vaccine for HIV/AIDS, developed through collaboration between Immuno Cure and the AIDS Institute at the University of Hong Kong. This marks a significant milestone in the development of the Hetao Shenzhen-Hong Kong Science and Technology Innovation Co-operation Zone.
This collaboration is witnessed by a Hong Kong Government delegation led by the Director of Health, Dr. Ronald LAM, and a Shenzhen Government delegation led by the Deputy Director General of Public Hygiene and Health Commission of Shenzhen Municipality, Ms. ZHOU Liping, following their GBA Clinical Trial Collaboration meeting held in Shenzhen.
GBAICTI and the BAY TRIAL plan to establish the GBA Clinical Trial Collaboration Platform (“Platform“) by the end of this year. The Platform is expected to offer a range of services, including project evaluation, trial design consultation, and subject recruitment planning for multi-centre clinical trials, provided by a joint Shenzhen-Hong Kong advisory team; integration of artificial intelligence technologies to assist with matching clinical trial institutions and researchers, as well as offering intelligent consultation services; establishment of a coordinated ethics review mechanism between the two regions to enhance approval efficiency; promotion of talent exchange, collaboration, and professional training; creation of a research talent pool to facilitate talent mobility and regional collaboration; and as a pilot, the development of clinical databases and biobanks based on disease areas of strength in both Shenzhen and Hong Kong.
Professor Bernard CHEUNG Man-yung, Chief Executive Officer of GBAICTI, said: “The ICVAX vaccine, developed by Immuno Cure and the AIDS Institute at the University of Hong Kong, is now poised for cross-border clinical trials in the Greater Bay Area. This highlights the achievements and potential of innovation and technology in China and the Hong Kong SAR. If the clinical trial results are positive, the new vaccine would bring hope to HIV/AIDS patients worldwide, particularly in Belt and Road countries. We aim to leverage the strength of both Guangdong and Hong Kong to establish the Guangdong-Hong Kong-Macao Greater Bay Area as a global hub for clinical trials.”
Dr. LI Yichong, Director of BAY TRIAL, said: “This collaboration marks the first cross border clinical trial project between the BAY TRIAL and Hong Kong, signifying a new phase in the cooperation between Shenzhen and Hong Kong in the biopharmaceutical sector of GBA. We will fully leverage the synergistic advantages of both regions to establish an international clinical trial platform with the BAY TRIAL, continuously injecting new momentum into the high-quality development of the Bay Area’s pharmaceutical and medical device industry.”
Since the first discovery of AIDS in 1981, 40 million people have died from HIV infection. Currently, there are still over 39 million people living with HIV worldwide. Although antiretroviral therapy (“ART“) can effectively control HIV, it cannot cure the disease, highlighting the importance of immunotherapy. Immunotherapy aims to enhance the host’s immune response, with the expectation of controlling viral replication without ART, ultimately achieving complete viral suppression and functional cure. Immuno Cure’s ICVAX induces broad-spectrum, multifunctional virus-specific T cells to achieve the goal of controlling viral replication without ART.
Immuno Cure completed the first-in-human Phase I clinical trial of the ICVAX vaccine in November 2024. The results demonstrated excellent safety and good immunogenicity. This year, two multi-center Phase II clinical trials will be conducted to evaluate the mechanism of action and efficacy, respectively, of ICVAX in humans. Both are randomized, double-blind, placebo-controlled, dose-escalation studies, with clinical trial centres in the Prince of Wales Hospital in Hong Kong and eight Grade 3A hospitals in China, including The Third People’s Hospital of Shenzhen, Beijing Ditan Hospital, Beijing Youan Hospital, Guangzhou Eighth People’s Hospital, Tianjin Second People’s Hospital, The Sixth People’s Hospital of Zhengzhou, Chengdu Public Health Clinical Medical Center, and Chongqing Public Health Medical Center.
Dr. Xia JIN, Chief Executive Officer of Immuno Cure, said: “We are delighted to receive support from both GBAICTI and BAY TRIAL, integrating medical resources from both regions to advance Immuno Cure’s therapeutic vaccine for HIV, ICVAX, to multi-center Phase II clinical trials. We will continue to collaborate with the HKU AIDS Institute to drive innovation in drug development, leverage local advantages in drug research and translation, accelerate ICVAX towards commercialization, provide more effective treatment options for HIV patients, and contribute to global health.”
GBAICTI, BAY TRIAL, and Immuno Cure look forward to further deepening clinical trial cooperation between Shenzhen and Hong Kong in future collaborations, jointly promoting the development and globalisation of innovative drug development, and supporting the national “Healthy China” strategic goals.
Hashtag: #ImmunoCure #醫克生物 #医克生物
https://www.immunocure.hk/
https://www.linkedin.com/company/immuno-cure/
The issuer is solely responsible for the content of this announcement.
About GBAICTI
The Greater Bay Area International Clinical Trial Institute (GBAICTI) is located in the Hong Kong Park of the Hetao Shenzhen-Hong Kong Science and Technology Innovation Co-operation Zone. Its mission is to coordinate public and private medical resources in Hong Kong, providing a one-stop support platform for research institutions. This aims to promote process optimization, talent training, and collaboration within the Greater Bay Area, accelerating the research and development of drugs and medical devices, allowing research outcomes to benefit patients more quickly. By closely collaborating with the Greater Bay Area International Clinical Trials Center, it leverages the unique advantages of “one institute, one center” to jointly coordinate cross-border, multi-center clinical trials that meet international standards.
To learn more about GBAICTI, please visit: https://gbaicti.hk/
About BAY TRIAL
The Greater Bay Area International Clinical Trials Center (BAY TRIAL) is a key initiative in implementing the “Notice of the State Council on Issuing the Development Plan for the Shenzhen Park of the Hetao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone” (State Council [2023] No. 12). It serves as strong support for Shenzhen’s development as an international science and technology innovation centre and for promoting the high-quality development of the biopharmaceutical industry in the Guangdong-Hong Kong-Macao Greater Bay Area (GBA). Located in the Hetao Shenzhen-Hong Kong Cooperation Zone, BAY TRIAL leverages the zone’s unique geographical and policy advantages to integrate clinical trial innovation resources across the GBA, deepen Shenzhen-Hong Kong science and technology collaboration, and establish a one-stop clinical trial platform. This platform provides top-tier clinical trial technical support, operational management, and registration services for domestic and international pharmaceutical and medical device R&D institutions. Additionally, BAY TRIAL will act as a “testing ground” for clinical trial regulation reforms and a “catalyst” for technological innovation, facilitating the alignment of clinical trial regulations and standards with international benchmarks, promoting the development and application of cutting-edge trial technologies, building a collaborative medical technology innovation network in the GBA, and enhancing the region’s competitiveness in the pharmaceutical and medical device industry.
To learn more about BAY TRIAL, please visit: https://baytrial.smart.org.cn/about/index.html
About Immuno Cure
Immuno Cure is a clinical stage biotechnology group based in the Hong Kong Science Park, focusing on research and development of innovative DNA medicines and antibody immunotherapies to fight against cancers, inflammatory and infectious diseases based on its patented PD-1-enhanced DNA Vaccine, Anti-Δ42PD1 Antibody; and Vaccine Delivery platforms.
To learn more about Immuno Cure, please visit: www.immunocure.hk
Media OutReach
PolyU research teams and startups shine at CES 2026, winning three prestigious innovation awards
Prof. Christopher CHAO, PolyU Senior Vice President (Research and Innovation), remarked, “PolyU is committed to nurturing innovative research talent with both national and international outlooks. We empower our teams by leading them to major international innovation events and fostering close collaboration among industry, academia, research and investment sectors on a global level, creating opportunities for the overseas expansion of PolyU startups. PolyU was the sole university from Hong Kong to exhibit at the event, with its participating teams making up 30% of the Hong Kong delegation, contributing to Hong Kong’s advancement into an international innovation and technology hub. Our record-breaking performance at this year’s CES affirms international recognition of PolyU research and innovation, propelling our teams to continue striving along the path of innovation and technology to create even more profound social impact.”
Leveraging its robust research strengths and its unique startup ecosystem, PolyVentures, the University actively supports its research teams and startups in developing innovative technologies, bringing Hong Kong research achievements to the global stage. The Smart Firefighting Robot, developed by Mr WANG Meng, a PhD candidate of the Department of Building Environment and Energy Engineering as well as Founder of PolyU startup Widemount Dynamics Tech Limited, along with his team, achieved the highest score in the “Products in Support of Human Security for All” category and earned the prestigious “Best of Innovation Award”. The Powered Rehab Skateboard, developed by Prof. Kenneth FONG, Associate Dean of the Graduate School and Associate Head of the Department of Rehabilitation Sciences, received an “Innovation Award” in the “Accessibility and Longevity” category. The FattaLab® Fatty Liver Diagnostic Device, developed by a team spearheaded by Prof. ZHENG Yongping, Henry G. Leong Professor in Biomedical Engineering, Chair Professor of Biomedical Engineering, and Founder and Chief Scientist of PolyU startup Eieling Technology Limited, also won an “Innovation Award” in the “Digital Health” category.
The three award-winning innovations aim to enhance human security or health through cutting-edge technologies. The AI-driven Smart Firefighting Robot features autonomous patrol, burning materials classification, fire extinguishing and real-time data sharing functions in smoke-filled environments, protecting firefighters and the public simultaneously. The Powered Rehab Skateboard is a portable and cost-effective robotic system that supports home-based and community rehabilitation for stroke patients. The skateboard facilitates motor recovery in hemiparetic upper limbs and allows users to engage in effective therapy. The FattaLab® Fatty Liver Diagnostic Device is the world’s first lightweight intelligent assessment system for fatty liver detection. Weighs only 120 grams, the device can complete fatty liver assessment within 30 seconds, achieving detection accuracy at medical-grade standards.
Organised by the Consumer Technology Association, CES is one of the world’s largest and most influential consumer electronics exhibitions, spotlighting cutting-edge technologies for modern living. This year, CES attracted over 4,500 exhibitors from around the globe. The PolyU startups participating in the exhibition were as follows:
| PolyU Startups | Featured Innovations | Company Representatives |
| AniMed Technology Limited | Contactless real-time AI-driven health monitoring | Dr LYU Weimin Co-founder and CEO, AniMed Technology Limited |
| CyanSE Smart Energy Tech Limited | AI-powered energy optimisation platforms for smart buildings | Ms Amber ZHANG Co-founder, CyanSE Smart Energy Tech Limited |
| DRESIO Limited | AI-powered physiotherapy assessments software solution | Mr Alexander YING CEO, DRESIO Limited |
| Eieling Technology Limited | FattaLab® Fatty Liver Diagnostic Device (CES 2026 Innovation Award) |
Prof. ZHENG Yongping Henry G. Leong Professor in Biomedical Engineering, Chair Professor of Biomedical Engineering, PolyU; Founder and Chief Scientist, Eieling Technology Limited |
| Entoptica Limited | Cutting-edge ophthalmic diagnostic technologies | Dr Mukhit KULMAGANBETOV Senior Research Fellow, InnoHK Centre for Eye and Vision Research; CEO, Entoptica Limited |
| Feelings Group Limited | AI-powered computer vision solution | Dr WONG Wing-sze Research Assistant Professor, Department of Language Science and Technology, PolyU; Clinical Consultant and Co-inventor, Feelings Group Limited Ms YIP Chi-hay |
| Gembody Limited | Next-generation portable AI ultrasound system | Ms MAO Qian CEO, Gembody Limited Dr YANG Fan CTO, Gembody Limited |
| ImageVector MedTech Limited | AI-Vision for Joint Degeneration
|
Dr JIANG Tianshu
Executive Director, ImageVector MedTech Limited |
| Immune Materials Limited | Innovative long-lasting antimicrobial self-disinfection materials | Prof. Chris LO Kwan-yu Professor, Department of Logistics and Maritime Studies, PolyU; Co-founder, Immune Materials Limited Prof. KAN Chi-wai |
| Innobound Limited | Portable smart terminal for emotional interaction, health monitoring and daily living assistance | Ms GAO Lan CEO and Founder, Innobound Limited |
| MedVision Limited | AI-powered medical imaging solution | Prof. CAI Jing Head and Professor, Department of Health Technology and Informatics, PolyU; Consultant, MedVision Limited Dr MA Zongrui |
| Mirror Caring Limited | Knee health management solution | Prof. Stephen WANG Jia Professor, School of Design, PolyU; Founder, Mirror Caring Limited |
| Nuvatech Limited | Next-Gen Fashion OS powered by Multi-modal AI | Mr DENG Yanheng Founder, Nuvatech Limited |
| On-Skin Wearable Technology Limited | Wearable Biomedical Electronic Device | Dr Rayman GONG Founder and CEO, On-Skin Wearable Technology Limited |
| ReSaTech Limited | AI solutions for product reliability | Mr Ricky LAW CEO, ReSaTech Limited |
| UbiquiTech Innovations Limited | Edge-AI robot for autonomous inspection and cleaning in confined spaces | Prof. CAO Jiannong Vice President (Education), Otto Poon Charitable Foundation Professor in Data Science, Chair Professor of Distributed and Mobile Computing, PolyU; Founder and Chief Scientist, UbiquiTech Innovations Limited Dr LIANG Zhixuan |
| Vcare Vision Technology Limited | Non-invasive myopia prevention solution | Dr TANG Yuk-ming Senior Lecturer, Department of Industrial and Systems Engineering, PolyU; Co-founder, Vcare Vision Technology Limited |
| Widemount Dynamics Tech Limited | Smart Firefighting Robot
(CES 2026 Best of Innovation Award) |
Mr WANG Meng PhD candidate, Building Environment and Energy Engineering, PolyU; Founder, Widemount Dynamics Tech Limited |
| XOXO Beverages Limited | Automated Cocktail Machine for improvements event and hospitality efficiency | Mr Nicholas YU Wo-ping Founder, XOXO Beverages Limited |
Hashtag: #PolyU
The issuer is solely responsible for the content of this announcement.
Media OutReach
Starlight Centre Launches New Program For Students with Autism Entering Mainstream Primary Schools.
Peer Modeling
Starlight Centre has provided specialised care services for children with high-functioning autism from primary 1 to 6 and have supported many students who are now ready to demonstrate positive behaviours from the programmes. Through peer modelling, younger students can observe and learn from their more experienced peers, helping them understand the acceptable boundaries of good behaviour.
RISE™
The Starlight RISE™ Primary School Readiness Program effectively prepares young children for formal education by developing their physical, social, emotional, and cognitive skills through engaging, play-based activities.
By actively involving parents in the process through comprehensive evaluations and strong partnerships, Starlight Centre aims to make parents feel valued and confident that their child’s development is being supported holistically, beyond just basic skills.
Hashtag: #AutismEducation #SpecialNeedsEducation #EarlyChildhoodEducation #ParentingSupport #StarlightCentre
The issuer is solely responsible for the content of this announcement.
About Starlight Centre
Starlight was founded by a group of parents and seasoned autism professionals who have experienced first-hand the challenges of finding the most effective therapy programs, preschools, and after-school care services. We understand what you’re going through and are here to help. No matter your child’s needs, come to us, and we will connect you with the right resources.
Media OutReach
Final Weeks to Visit UABBHK 2025 — Explore AI-Enhanced Architecture Before Exhibition Closes on 24 January
Reimagining Architecture as Civic Performance
Under the theme “TECHFORMANCE: Technology, Platform and Performance”, UABBHK 2025 explores how artificial intelligence (AI) is reshaping the architectural discipline — from static design to dynamic, participatory experience. Featuring over 25 exhibits across two venues, the Biennale brings together architects, designers, artists, and researchers to examine how emerging technologies such as generative design, robotics, immersive media, and machine learning are transforming authorship, spatial storytelling, and public engagement.
Exhibits Worth Revisiting
As the Biennale draws to a close, the curatorial team invites visitors to experience some of the most thought-provoking and visually striking works.
At Oi!, “Sanctum in the AI Age: Redefining the Human-Deities Nexus in Urban Future” by Jessica Kong and Nam Wu offers a compelling exploration of AI-generated shrine designs and spirituality in hyper-dense urban contexts. Nearby, “Island Totem” by Island Works presents a poetic memorial column using water, light, and soundscape to reflect on the overlooked histories and geographies of Hong Kong’s islands.
At EKCC, “Sentient Mirror – Genius Loci” by XCEPT invites visitors to contribute personal memories and emotional data which are transformed into a dynamic “memory-scape” of Hong Kong architecture. “Stone Synergy: AI-Driven Community Housing” by Olivia Chen proposes a design platform that empowers communities to co-create sustainable housing using local materials and machine learning. In “Collaborative Ephemeral Pavilion – Design with Technology”, Prof. Tris Kee and students from The Hong Kong Polytechnic University repurpose metal scaffolding into a community-built pavilion that shares local stories through interactive media. Meanwhile, “Computational BioPhilia: Culture-Nature Synthesis in Biomimicry Fabrication” by Patrick So, Bojia Xiao and Polly Heng presents a biodegradable architectural prototype that nurtures soil regeneration using AI and modular design, blending ecological restoration with digital fabrication.
Upcoming Programmes — Tech Sunday and Guided Tours
On 18 January 2026, UABBHK 2025 will host its final Tech Sunday at Oi!, featuring two sessions. The morning session, “Cultural Identity & Ritual in the AI-Enhanced Urban Realm”, includes presentations by Ashley Wong, Jessica Kong, and Vicky Lam, exploring informal shrines, afterlife economies, and AI-generated flower market futures. In the afternoon, “Craft, Algorithm, and Robotic Fabrication” brings together Kristof Crolla, Garvin Goepel, Su Chang, and others to discuss AI-enabled design and fabrication practices.
To complement the forums, free guided tours are available at both venues on 11 and 18 January. Prior registration is available at UABBHK 2025’s website.
Cross-Border Dialogue Continues in Shenzhen
Beyond the Hong Kong venues, UABBHK 2025 is also being showcased in the Shenzhen & Hong Kong Bi-city Biennale of Urbanism Architecture (Shenzhen) (UABBSZ), which has been opened on 31 December 2025, at the Hetao Science and Technology Innovation Center. Themed as “City Theater”, UABBSZ positions Shenzhen as a city of performative stage where architecture, technology, and civic life intersect. In Shenzhen, a symbolic tunnel portal installation of UABBHK 2025 is set, linking Shenzhen and Hong Kong as a gesture of spatial and curatorial continuity.
Exhibition and Admission Details of Hong Kong part of UABBHK 2025
- Venues:
- Oil Street Art Space (Oi!), 12 Oil Street, North Point
- East Kowloon Cultural Centre (EKCC), 60 Ngau Tau Kok Road, Kowloon
- Exhibition Period:
Now until 24 January 2026 - Admission:
Free - Link to free guided tours registration:
https://uabb2025.hkia.org.hk/en/programme
For updated schedules, programme registration, and more information, please visit UABBHK 2025’s website: https://uabb2025.hkia.org.hk/en. For detailed exhibitor list and installation descriptions, please refer to the appendix.Hashtag: #UABBHK
The issuer is solely responsible for the content of this announcement.
About The Hong Kong Institute of Architects Biennale Foundation
The Hong Kong Institute of Architects Biennale Foundation is a non-profit making organisation established and incorporated in 2014 for charitable purposes. The objects for which the Biennale Foundation is established are:
- To promote creativity and advance the understanding, appreciation and interest of architectural and design excellence
- To encourage cross-border and cross-disciplinary dialogue and collaboration among creative professionals from Hong Kong, other parts of the Greater China region and overseas
- To support art, design, architectural and cultural education for students and youth, the community, and policy makers
- To create a favourable environment for study, research and experimentation of design, art and architectural works in an exhibition scale
- To energise and revitalise specific sites of interests by introduction of cultural and creative events
About the Cultural and Creative Industries Development Agency
The Cultural and Creative Industries Development Agency (CCIDA), formerly known as Create Hong Kong (CreateHK) since 2009, was established in June 2024. CCIDA is a dedicated office under the Culture, Sports and Tourism Bureau of the Government of the Hong Kong Special Administrative Region (HKSAR Government) to provide one-stop services and support to the cultural and creative sectors with a mission to foster a conducive environment in Hong Kong to facilitate development of the arts, culture and creative sectors as industries. CCIDA’s strategic foci are nurturing talent and facilitating start-ups, exploring markets, promoting cross-sectoral and multi-disciplinary collaboration, promoting industrialisation of the arts, culture and creative sectors under the industry-oriented principle, and fostering a creative atmosphere in the community, thereby reinforcing Hong Kong as Asia’s creative capital and our positioning as the East-meets-West centre for international cultural exchange.
2025 Hong Kong & Shenzhen Bi-City Biennale of UrbanismArchitecture (Hong Kong)’s Disclaimer:
The Cultural and Creative Industries Development Agency of the Government of the Hong Kong Special Administrative Region provides funding support to the project only, and does not otherwise take part in the project. Any opinions, findings, conclusions or recommendations expressed in these materials/events (or by members of the project team) are those of the project organisers only and do not reflect the views of the Government of the Hong Kong Special Administrative Region, the Culture, Sports and Tourism Bureau, the Cultural and Creative Industries Development Agency, the CreateSmart Initiative Secretariat or the CreateSmart Initiative Vetting Committee.
-
Feature/OPED6 years agoDavos was Different this year
-
Travel/Tourism9 years ago
Lagos Seals Western Lodge Hotel In Ikorodu
-
Showbiz3 years agoEstranged Lover Releases Videos of Empress Njamah Bathing
-
Banking8 years agoSort Codes of GTBank Branches in Nigeria
-
Economy3 years agoSubsidy Removal: CNG at N130 Per Litre Cheaper Than Petrol—IPMAN
-
Banking3 years agoFirst Bank Announces Planned Downtime
-
Banking3 years agoSort Codes of UBA Branches in Nigeria
-
Sports3 years agoHighest Paid Nigerian Footballer – How Much Do Nigerian Footballers Earn